【摘要】 腹膜透析(peritoneal dialysis,PD)作为肾脏替代治疗方式之一，在终末期肾衰竭患者的治疗中占有不可替代的地位。然而，长期的腹膜透析会影响腹膜的功能和结构。腹膜纤维化(peritoneal fibrosis,PF)是长期腹膜透析患者的严重并发症，可导致超滤失败(ultrafiltration failure,UFF)和腹膜透析的中断。近年来，间充质干细胞(mesenchymal stromal cells,MSCs)因其多向分化潜能、免疫调节和组织修复作用成为一个具有临床应用潜力的创新科学研究领域。最近研究表明间充质干细胞可以通过调节炎症、修复损伤以及抑制腹膜间皮细胞的上皮-间充质转化(epithelial-to-mesenchymal transition,EMT)来改善腹膜纤维化。本文就间充质干细胞延缓腹膜纤维化的机制、相关研究和存在的问题等方面进行综述。更多还原

【Abstract】 Peritoneal dialysis(PD) is one of the kidney replacement treatments and plays an irreplaceable role in the treatment of end-stage renal failure patients. However, long-term PD can affect the function and structure of the peritoneum. Peritoneal fibrosis is a serious complication in long-term PD patients, leading to ultrafiltration failure and interruption of PD. In recent years, mesenchymal stem cells(MSCs) have become an innovative research field with clinical application potential due to their multi-directional differentiation potential, immunomodulatory and tissue repair abilities. Recent studies have shown that MSCs can ameliorate peritoneal fibrosis by regulating inflammation, repairing damage, and inhibiting epithelial-mesenchymal transformation(EMT) of the peritoneal mesenchymal cells. This article reviews the mechanism, research progresses and difficulties of MSCs used for delaying peritoneal fibrosis.更多还原